Review



sti target  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier
Bioz Manufacturer Symbol Bio-Rad manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Bio-Rad sti target
    Sti Target, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 95/100, based on 97 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sti+target/GS+HIV+Combo+Ag%2FAb+EIA/10__5858_slash_arpa__2019___0901___ab-9876-0-13
    Average 95 stars, based on 97 article reviews
    sti target - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Virus:

    Article Title: Abstracts and Case Studies From the College of American Pathologists 2019 Annual Meeting (CAP19)
    Article Snippet: .. STI Target Product Name Source Human immunodeficiency virus GS HIV Combo Ag/Ab EIA Bio-Rad Laboratories (Hercules, California) Hepatitis C Ortho HCV Version 3.0 ELISA Test System Bio-Rad Laboratories (Hercules, California) Herpes simplex virus 2 HerpeSelect 2 ELISA IgG Focus Diagnostics (Cypress, California) Syphilis Trep-Sure Syphilis Total Antibody EIA Trinity Biotech (Bray, Ireland) Cribriform-Morular Variant of Papillary Thyroid Carcinoma With Associated Familial Adenomatous Polyposis (Poster No. 139) Katherine Cochrane, MD (kcochrane@utmck.edu); George Sneed, DO. ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Abstracts and Case Studies From the College of American Pathologists 2019 Annual Meeting (CAP19)
    Article Snippet: .. STI Target Product Name Source Human immunodeficiency virus GS HIV Combo Ag/Ab EIA Bio-Rad Laboratories (Hercules, California) Hepatitis C Ortho HCV Version 3.0 ELISA Test System Bio-Rad Laboratories (Hercules, California) Herpes simplex virus 2 HerpeSelect 2 ELISA IgG Focus Diagnostics (Cypress, California) Syphilis Trep-Sure Syphilis Total Antibody EIA Trinity Biotech (Bray, Ireland) Cribriform-Morular Variant of Papillary Thyroid Carcinoma With Associated Familial Adenomatous Polyposis (Poster No. 139) Katherine Cochrane, MD (kcochrane@utmck.edu); George Sneed, DO. ..

    Variant Assay:

    Article Title: Abstracts and Case Studies From the College of American Pathologists 2019 Annual Meeting (CAP19)
    Article Snippet: .. STI Target Product Name Source Human immunodeficiency virus GS HIV Combo Ag/Ab EIA Bio-Rad Laboratories (Hercules, California) Hepatitis C Ortho HCV Version 3.0 ELISA Test System Bio-Rad Laboratories (Hercules, California) Herpes simplex virus 2 HerpeSelect 2 ELISA IgG Focus Diagnostics (Cypress, California) Syphilis Trep-Sure Syphilis Total Antibody EIA Trinity Biotech (Bray, Ireland) Cribriform-Morular Variant of Papillary Thyroid Carcinoma With Associated Familial Adenomatous Polyposis (Poster No. 139) Katherine Cochrane, MD (kcochrane@utmck.edu); George Sneed, DO. ..



    Similar Products

    lutetium target  (ISOFLEX)
    90
    ISOFLEX lutetium target
    Lutetium Target, supplied by ISOFLEX, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sti+target/Lutetium-176/pm34402687-52-15-20
    Average 90 stars, based on 1 article reviews
    lutetium target - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    targeted intervention (ti) centre/sti clinic  (Khushi Inc)
    90
    Khushi Inc targeted intervention (ti) centre/sti clinic
    Targeted Intervention (Ti) Centre/Sti Clinic, supplied by Khushi Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sti+target/sti+clinic/pm31439184-56-34-37
    Average 90 stars, based on 1 article reviews
    targeted intervention (ti) centre/sti clinic - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sti target  (Bio-Rad)
    95
    Bio-Rad sti target
    Sti Target, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sti+target/GS+HIV+Combo+Ag%2FAb+EIA/10__5858_slash_arpa__2019___0901___ab-9876-0-13
    Average 95 stars, based on 1 article reviews
    sti target - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    sti-571/imatinib, a multi-target inhibitor of v-abl, c-kit and pdgfr  (Selleck Chemicals)
    90
    Selleck Chemicals sti-571/imatinib, a multi-target inhibitor of v-abl, c-kit and pdgfr
    (A) Phospho-RTK array analysis of MDA1386 cell lysate. The positive (+) controls are the built–in reference spots at the three corners of the array blot. Black arrows pointed to the positions corresponding to the respective RTK on the blot. Noted the <t>strong</t> <t>EGFR</t> and MET phosphorylation signals, the weaker IGF-1R and Axl signals and the absent <t>PDGFR</t> signal. (B) MDA1386 cell response to the MET TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (C) MDA1386 cell response to the IGF-1R TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (D) MDA1386 cell response to the dual inhibition of MET and EGFR in comparison to MET or EGFR inhibition alone at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Noted the increase in cell growth inhibition with dual MET and EGFR TKI at 10 uM. Tx: treatment; NS: not significant. Error bars represent ±2 standard errors.
    Sti 571/Imatinib, A Multi Target Inhibitor Of V Abl, C Kit And Pdgfr, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sti+target/sti571/pmc05765765-160-55-7
    Average 90 stars, based on 1 article reviews
    sti-571/imatinib, a multi-target inhibitor of v-abl, c-kit and pdgfr - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pure enriched molybdenum target  (ISOFLEX)
    94
    ISOFLEX pure enriched molybdenum target
    (A) Phospho-RTK array analysis of MDA1386 cell lysate. The positive (+) controls are the built–in reference spots at the three corners of the array blot. Black arrows pointed to the positions corresponding to the respective RTK on the blot. Noted the <t>strong</t> <t>EGFR</t> and MET phosphorylation signals, the weaker IGF-1R and Axl signals and the absent <t>PDGFR</t> signal. (B) MDA1386 cell response to the MET TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (C) MDA1386 cell response to the IGF-1R TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (D) MDA1386 cell response to the dual inhibition of MET and EGFR in comparison to MET or EGFR inhibition alone at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Noted the increase in cell growth inhibition with dual MET and EGFR TKI at 10 uM. Tx: treatment; NS: not significant. Error bars represent ±2 standard errors.
    Pure Enriched Molybdenum Target, supplied by ISOFLEX, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sti+target/Molybdenum-98/10__3367_slash_ufne__0185__201501f__0077-149-15-21
    Average 94 stars, based on 1 article reviews
    pure enriched molybdenum target - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    targeted therapy imatinib mesylate sti-571 glivec  (Novartis)
    90
    Novartis targeted therapy imatinib mesylate sti-571 glivec
    Neoadjuvant and adjuvant trials of <t> imatinib </t> in GIST
    Targeted Therapy Imatinib Mesylate Sti 571 Glivec, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sti+target/imatinib/pmc02503651-61-9-16
    Average 90 stars, based on 1 article reviews
    targeted therapy imatinib mesylate sti-571 glivec - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Phospho-RTK array analysis of MDA1386 cell lysate. The positive (+) controls are the built–in reference spots at the three corners of the array blot. Black arrows pointed to the positions corresponding to the respective RTK on the blot. Noted the strong EGFR and MET phosphorylation signals, the weaker IGF-1R and Axl signals and the absent PDGFR signal. (B) MDA1386 cell response to the MET TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (C) MDA1386 cell response to the IGF-1R TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (D) MDA1386 cell response to the dual inhibition of MET and EGFR in comparison to MET or EGFR inhibition alone at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Noted the increase in cell growth inhibition with dual MET and EGFR TKI at 10 uM. Tx: treatment; NS: not significant. Error bars represent ±2 standard errors.

    Journal: International journal of cancer

    Article Title: A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers

    doi: 10.1002/ijc.31045

    Figure Lengend Snippet: (A) Phospho-RTK array analysis of MDA1386 cell lysate. The positive (+) controls are the built–in reference spots at the three corners of the array blot. Black arrows pointed to the positions corresponding to the respective RTK on the blot. Noted the strong EGFR and MET phosphorylation signals, the weaker IGF-1R and Axl signals and the absent PDGFR signal. (B) MDA1386 cell response to the MET TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (C) MDA1386 cell response to the IGF-1R TKI at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Tx: treatment; NS: not significant. Error bars represent ±2 standard errors. (D) MDA1386 cell response to the dual inhibition of MET and EGFR in comparison to MET or EGFR inhibition alone at three different concentrations (1, 5 and 10 uM, n = 3 at each concentration for each treatment). Noted the increase in cell growth inhibition with dual MET and EGFR TKI at 10 uM. Tx: treatment; NS: not significant. Error bars represent ±2 standard errors.

    Article Snippet: The following small molecular TKIs were purchased (Selleck Chemicals): (1) JNJ-38877605, a highly selective, ATP-competitive inhibitor of c-MET ( 25 ); (2) NVP-AEW541, a potent inhibitor of IGF-1R with IC 50 of 86 nM ( 26 ); (3) OSI-744/erlotinib HCl, a FDA approved EGFR inhibitor and (4) STI-571/imatinib, a multi-target inhibitor of v-Abl, c-Kit and PDGFR.

    Techniques: Concentration Assay, Inhibition

    Neoadjuvant and adjuvant trials of imatinib in GIST

    Journal: Therapeutics and Clinical Risk Management

    Article Title: Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

    doi:

    Figure Lengend Snippet: Neoadjuvant and adjuvant trials of imatinib in GIST

    Article Snippet: This has led to the development of the targeted therapy imatinib mesylate (STI-571; Glivec ® , Novartis, Basel, Switzerland).

    Techniques: Adjuvant, Expressing, Mutagenesis